Georgetown University Lombardi Comprehensive Cancer Center Support Grant

摘要 乔治城隆巴迪综合癌症中心（LCCC）是唯一一家由NCI指定的综合癌症中心。 位于首都的癌症中心由路易斯·M。Weiner MD自2008年以来，LCCC的愿景是防止 并以当地为重点和全球影响力治愈癌症。我们的使命是预防、治疗和治愈癌症， 科学发现，专家和富有同情心的病人护理，优质教育，以及与 社区，以“照顾整个人”的人身安全原则为指导。LCCC的战略目标 1）推进变革性癌症研究，2）减少癌症的影响，缩小我们的差距， 集水区，3）领导高影响力的临床研究，4）确保长期增长，活力和稳定的 研究企业，5）培养下一代癌症科学家，临床医生和教育工作者。这些 通过LCCC与约翰·特雷尔癌症中心（JTCC）的深化关系， Hackensack Meridian Health（HMH）是一家临床和临床研究机构， 研究基地和扩大LCCC的影响。通过此P30竞争性续约申请，LCCC正在申请 CCSG财团与JTCC，满足CCSG FOA外部资金要求。LCCC联盟 由位于华盛顿特区的乔治城隆巴迪综合癌症中心（LCCC-DC）组成 以及位于新泽西州哈肯萨克的哈肯萨克子午线健康约翰·特雷尔癌症中心（LCCC-NJ）。 因此，LCCC的服务区由LCCC-DC和LCCC-NJ服务区定义。LCCC 研究基于四个研究项目：乳腺癌（BC），癌症预防和控制（CPC）， 实验治疗学（ET）和分子肿瘤学（MO）。数据科学中的跨领域举措，少数群体 健康和健康差距，癌症精准医疗，免疫疗法和癌症生存重点， 支持这些项目的工作。在当前的CCSG资助周期内，LCCC采用了一个强大的战略 规划过程，以发展和完善其研究。LCCC进行的研究正在改变实践， 范式转变和政策通报，114名成员在2015年期间发表了1，390篇论文（18%的IF>8）。 当前CCSG融资周期。目前，LCCC成员的癌症重点年度直接费用资助是 36 696 492美元（其中3 282 510美元来自新泽西州LCCC的成员）。LCCC有2，165例介入性临床 2014-2017年在其DC集水区的试验累积，该集水区由DC的400多万人组成 以及马里兰州和弗吉尼亚州的每个周边县。LCCC的卑尔根县NJ集水区包含 近100万居民LCCC通过提供这些服务，增加了临床研究和护理的机会 大的、种族和民族多样化的集水区，因乳腺癌、前列腺癌 胰腺癌和肝癌。未来的计划包括扩大针对集水区需求的研究， 特别强调血液恶性肿瘤和细胞疗法的转化和临床研究。

ABSTRACT The Georgetown Lombardi Comprehensive Cancer Center (LCCC) is the only NCI-designated comprehensive cancer center based in the nation’s capital. Led by Louis M. Weiner MD since 2008, LCCC’s vision is to prevent and cure cancer with a local focus and global impact. Our mission is to prevent, treat, and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis, “care for the whole person.” LCCC’s strategic objectives are to 1) advance transformative cancer research, 2) reduce the impact of cancer and diminish disparities in our catchment area, 3) lead high-impact clinical research, 4) ensure long-term growth, vibrancy and stability of the research enterprise, and 5) develop the next generation of cancer scientists, clinicians and educators. These objectives were furthered by LCCC’s deepening relationship with the John Theurer Cancer Center (JTCC) of Hackensack Meridian Health (HMH), a clinical and clinical research powerhouse that brings a substantial research base and extends LCCC’s impact. With this P30 competitive renewal application LCCC is applying as a CCSG consortium with JTCC, which meets CCSG FOA external funding requirements. The LCCC Consortium is comprised of Georgetown Lombardi Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC-NJ catchment areas. LCCC research is based in four research programs: Breast Cancer (BC), Cancer Prevention and Control (CPC), Experimental Therapeutics (ET) and Molecular Oncology (MO). Crosscutting initiatives in data science, minority health and health disparities, cancer precision medicine, immunotherapy and cancer survivorship focus and support the work of these programs. During the current CCSG funding cycle, LCCC employed a robust strategic planning process to develop and refine its research. LCCC conducts research that is practice changing, paradigm shifting and policy informing, with 114 members publishing 1,390 papers (18% with IF>8) during the current CCSG funding period. Current cancer-focused annual direct cost funding for LCCC members is $36,696,492 (of which $3,282,510 is from members based at LCCC-NJ). LCCC had 2,165 interventional clinical trial accruals from 2014-2017 in its DC catchment area, which consists of more than four million people in DC and each surrounding county in Maryland and Virginia. LCCC’s Bergen County NJ catchment area contains nearly 1 million residents. LCCC has increased opportunities for clinical research and care by serving these large, racially and ethnically diverse catchment areas, which suffer from excess mortality from breast, prostate, pancreas and liver cancers. Future plans include expansion of research addressing catchment areas’ needs, with a particular emphasis on hematologic malignancies and cellular therapy translational and clinical research.